Healthcare [ 9/13 ] | Drug Manufacturers - Specialty & Generic [ 55/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 8, 23 | -0.08 Increased by +91.49% | -0.28 Increased by +71.43% |
| Aug 10, 23 | -0.4 Increased by +66.67% | -0.53 Increased by +24.53% |
| May 10, 23 | -0.75 Increased by +37.5% | -1.39 Increased by +46.04% |
| Mar 30, 23 | -1 Increased by +16.67% | -0.51 Decreased by -96.08% |
| Nov 14, 22 | -0.94 Increased by +32.86% | -1.2 Increased by +21.67% |
| Aug 11, 22 | -1.2 Increased by +25% | -1.5 Increased by +20% |
| May 16, 22 | -1.2 Increased by +25% | -1.2 |
| Mar 10, 22 | -1.2 Increased by +40% | -1.4 Increased by +14.29% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 281 K Increased by +11.51% | -4.52 M Increased by +39.64% | Decreased by -1.61 K% Increased by +45.87% |
| Sep 30, 23 | 117 K Decreased by -76.92% | -1.36 M Increased by +79.9% | Decreased by -1.16 K% Increased by +12.88% |
| Jun 30, 23 | 253 K Decreased by -55.61% | -4.37 M Decreased by -106.19% | Decreased by -1.73 K% Decreased by -113.94% |
| Mar 31, 23 | 0 Decreased by -100% | 5.34 M Increased by +163.89% | Increased by +N/A% Increased by +N/A% |
| Dec 31, 22 | 252 K Increased by +12.5 K% | -7.48 M Increased by +5.47% | Decreased by -2.97 K% Increased by +99.25% |
| Sep 30, 22 | 507 K Decreased by -72.77% | -6.75 M Increased by +19.4% | Decreased by -1.33 K% Decreased by -196% |
| Jun 30, 22 | 570 K Increased by +28.67% | 70.66 M Increased by +817.32% | Increased by +12.4 K% Increased by +657.49% |
| Mar 31, 22 | 442 K Decreased by -13.5% | -8.35 M Increased by +6.73% | Decreased by -1.89 K% Decreased by -7.83% |
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.